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Background:   
There is much advancement in treatment of chronic myeloid leukemia (CML) since the approval of 
first tyrosine kinase inhibitor (TKI), imatinib, by US FDA in 2001.  One of them is definitely the concept 
of stopping TKI, starting at the CML patients who have achieved deep molecular response (MR) of 
MR4.5 for a reasonable long period of at least two years, pioneered by the researchers from French 
and Australia.  Meanwhile, interferon, the standard treatment of CML before the era of TKI, showed 
that interferon-responded patients may indeed retain the response once interferon was withdrawn via 
interferon-induced immunity towards the leukemic clone.  This is further supported by stop trial in 
Japan, in which after stopping TKI, interferon was given for 2 years and it showed a higher drug-free 
rate compared to stop trial from French and Australia.  Hence, it is logical to postulate the use of 
interferon after TKI was stopped when patients have attained deep MR for more than two years will 
increase the percentage of patients remain TKI-free on follow-up. 
 
Materials and Methods: 
This is a multi-center randomized controlled trial.  Adult CML patients, diagnosed in chronic phase, 
treated with ongoing TKI for at least 3 years without previous history of TKI failure and have achieved 
stable deep MR on International Scale for ≥2 years with at least 2 readings of MR4.5 (including the 
latest before study entry), were randomized into 2 arms: (1) peginterferon-α-2a, subcutaneous weekly, 
starting at 180 mcg, or (2) observation.  Disease is monitored by PCR (centralized in Ampang 
Hospital) at monthly for the first year, 2 monthly for the second year and 3 monthly for the third year.  
Relapse is defined as either (i) one reading of loss of major MR, i.e. reading of >0.1% IS and 
confirmed by second analysis taken 1 month later if the first analysis point reading is ≤1% IS, or (ii) 
positivity of BCR-ABL1 transcripts, as confirmed by a second analysis point, indicating the increase 
(at least 1 log) in relation to the first analysis point at two successive assessments. Quality of Life is 
assessed using EORTC QLO-C30. 
 
Results: 
At the time of writing, total of 8 patients were randomized, 5 into peginterferon arm, 3 into observation 
arm, all were on imatinib, M:F = 4:4, Malay: Chinese:Indian = 3:4:1, median age 49.5 (range 25-58), 
median follow-up 4 months (range 1-6) and none of them relapse.  Two patients developed imatinib 
withdrawal syndrome, both female on observation arm, one was mild and resolved after 2 months but 
one was severe and needed termination after 2 months and restarted on imatinib.  Two patients in 
peginterferon arm developed mild hepatitis with liver enzymes <2x of ULN.  Four patients were able to 
tolerate peginterferon-α-2a at the dose of 180 mcg weekly, while one patient needed dose reduction 
to 90 mcg weekly.  Quality of life score comparing two months after stopping TKI and baseline will be 




No conclusive date can be drawn so far because sample size is small and follow-up is short.  
Nonetheless, this trial provides Malaysian CML a platform to stop TKI safely. 
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